Global Influenzavirus B Infection Drug Market Research Report 2024(Status and Outlook)
Report Overview
This report provides a deep insight into the global Influenzavirus B Infection Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Influenzavirus B Infection Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Influenzavirus B Infection Drug market in any manner.
Global Influenzavirus B Infection Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AbbVie Inc
Adimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioCryst Pharmaceuticals Inc
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Company Ltd
Fujifilm Holdings Corporation
GlaxoSmithKline Plc
Green Cross Corp
Inovio Pharmaceuticals Inc
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Park Active Molecules
Romark Laboratories LC
Sanofi
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc
Market Segmentation (by Type)
APP-309
CF-403
GC-3106A
KIN-1400
Others
Market Segmentation (by Application)
Clinic
Hospital
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Influenzavirus B Infection Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
This report provides a deep insight into the global Influenzavirus B Infection Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Influenzavirus B Infection Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Influenzavirus B Infection Drug market in any manner.
Global Influenzavirus B Infection Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AbbVie Inc
Adimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioCryst Pharmaceuticals Inc
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Company Ltd
Fujifilm Holdings Corporation
GlaxoSmithKline Plc
Green Cross Corp
Inovio Pharmaceuticals Inc
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Park Active Molecules
Romark Laboratories LC
Sanofi
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc
Market Segmentation (by Type)
APP-309
CF-403
GC-3106A
KIN-1400
Others
Market Segmentation (by Application)
Clinic
Hospital
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Influenzavirus B Infection Drug Market
- Overview of the regional outlook of the Influenzavirus B Infection Drug Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Influenzavirus B Infection Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Influenzavirus B Infection Drug
1.2 Key Market Segments
1.2.1 Influenzavirus B Infection Drug Segment by Type
1.2.2 Influenzavirus B Infection Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INFLUENZAVIRUS B INFECTION DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Influenzavirus B Infection Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Influenzavirus B Infection Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INFLUENZAVIRUS B INFECTION DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Global Influenzavirus B Infection Drug Sales by Manufacturers (2019-2024)
3.2 Global Influenzavirus B Infection Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Influenzavirus B Infection Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Influenzavirus B Infection Drug Sales Sites, Area Served, Product Type
3.6 Influenzavirus B Infection Drug Market Competitive Situation and Trends
3.6.1 Influenzavirus B Infection Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Influenzavirus B Infection Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 INFLUENZAVIRUS B INFECTION DRUG INDUSTRY CHAIN ANALYSIS
4.1 Influenzavirus B Infection Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INFLUENZAVIRUS B INFECTION DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 INFLUENZAVIRUS B INFECTION DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Influenzavirus B Infection Drug Sales Market Share by Type (2019-2024)
6.3 Global Influenzavirus B Infection Drug Market Size Market Share by Type (2019-2024)
6.4 Global Influenzavirus B Infection Drug Price by Type (2019-2024)
7 INFLUENZAVIRUS B INFECTION DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Influenzavirus B Infection Drug Market Sales by Application (2019-2024)
7.3 Global Influenzavirus B Infection Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Influenzavirus B Infection Drug Sales Growth Rate by Application (2019-2024)
8 INFLUENZAVIRUS B INFECTION DRUG MARKET SEGMENTATION BY REGION
8.1 Global Influenzavirus B Infection Drug Sales by Region
8.1.1 Global Influenzavirus B Infection Drug Sales by Region
8.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Influenzavirus B Infection Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Influenzavirus B Infection Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Influenzavirus B Infection Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Influenzavirus B Infection Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AbbVie Inc
9.1.1 AbbVie Inc Influenzavirus B Infection Drug Basic Information
9.1.2 AbbVie Inc Influenzavirus B Infection Drug Product Overview
9.1.3 AbbVie Inc Influenzavirus B Infection Drug Product Market Performance
9.1.4 AbbVie Inc Business Overview
9.1.5 AbbVie Inc Influenzavirus B Infection Drug SWOT Analysis
9.1.6 AbbVie Inc Recent Developments
9.2 Adimmune Corp
9.2.1 Adimmune Corp Influenzavirus B Infection Drug Basic Information
9.2.2 Adimmune Corp Influenzavirus B Infection Drug Product Overview
9.2.3 Adimmune Corp Influenzavirus B Infection Drug Product Market Performance
9.2.4 Adimmune Corp Business Overview
9.2.5 Adimmune Corp Influenzavirus B Infection Drug SWOT Analysis
9.2.6 Adimmune Corp Recent Developments
9.3 Altravax Inc
9.3.1 Altravax Inc Influenzavirus B Infection Drug Basic Information
9.3.2 Altravax Inc Influenzavirus B Infection Drug Product Overview
9.3.3 Altravax Inc Influenzavirus B Infection Drug Product Market Performance
9.3.4 Altravax Inc Influenzavirus B Infection Drug SWOT Analysis
9.3.5 Altravax Inc Business Overview
9.3.6 Altravax Inc Recent Developments
9.4 Amarillo Biosciences Inc
9.4.1 Amarillo Biosciences Inc Influenzavirus B Infection Drug Basic Information
9.4.2 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Overview
9.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Market Performance
9.4.4 Amarillo Biosciences Inc Business Overview
9.4.5 Amarillo Biosciences Inc Recent Developments
9.5 Aphios Corp
9.5.1 Aphios Corp Influenzavirus B Infection Drug Basic Information
9.5.2 Aphios Corp Influenzavirus B Infection Drug Product Overview
9.5.3 Aphios Corp Influenzavirus B Infection Drug Product Market Performance
9.5.4 Aphios Corp Business Overview
9.5.5 Aphios Corp Recent Developments
9.6 BioCryst Pharmaceuticals Inc
9.6.1 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
9.6.2 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
9.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Market Performance
9.6.4 BioCryst Pharmaceuticals Inc Business Overview
9.6.5 BioCryst Pharmaceuticals Inc Recent Developments
9.7 Cadila Healthcare Ltd
9.7.1 Cadila Healthcare Ltd Influenzavirus B Infection Drug Basic Information
9.7.2 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Overview
9.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Market Performance
9.7.4 Cadila Healthcare Ltd Business Overview
9.7.5 Cadila Healthcare Ltd Recent Developments
9.8 ContraFect Corp
9.8.1 ContraFect Corp Influenzavirus B Infection Drug Basic Information
9.8.2 ContraFect Corp Influenzavirus B Infection Drug Product Overview
9.8.3 ContraFect Corp Influenzavirus B Infection Drug Product Market Performance
9.8.4 ContraFect Corp Business Overview
9.8.5 ContraFect Corp Recent Developments
9.9 Daiichi Sankyo Company Ltd
9.9.1 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Basic Information
9.9.2 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Overview
9.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Market Performance
9.9.4 Daiichi Sankyo Company Ltd Business Overview
9.9.5 Daiichi Sankyo Company Ltd Recent Developments
9.10 Fujifilm Holdings Corporation
9.10.1 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Basic Information
9.10.2 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Overview
9.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Market Performance
9.10.4 Fujifilm Holdings Corporation Business Overview
9.10.5 Fujifilm Holdings Corporation Recent Developments
9.11 GlaxoSmithKline Plc
9.11.1 GlaxoSmithKline Plc Influenzavirus B Infection Drug Basic Information
9.11.2 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Overview
9.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Market Performance
9.11.4 GlaxoSmithKline Plc Business Overview
9.11.5 GlaxoSmithKline Plc Recent Developments
9.12 Green Cross Corp
9.12.1 Green Cross Corp Influenzavirus B Infection Drug Basic Information
9.12.2 Green Cross Corp Influenzavirus B Infection Drug Product Overview
9.12.3 Green Cross Corp Influenzavirus B Infection Drug Product Market Performance
9.12.4 Green Cross Corp Business Overview
9.12.5 Green Cross Corp Recent Developments
9.13 Inovio Pharmaceuticals Inc
9.13.1 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
9.13.2 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
9.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Market Performance
9.13.4 Inovio Pharmaceuticals Inc Business Overview
9.13.5 Inovio Pharmaceuticals Inc Recent Developments
9.14 Kineta Inc
9.14.1 Kineta Inc Influenzavirus B Infection Drug Basic Information
9.14.2 Kineta Inc Influenzavirus B Infection Drug Product Overview
9.14.3 Kineta Inc Influenzavirus B Infection Drug Product Market Performance
9.14.4 Kineta Inc Business Overview
9.14.5 Kineta Inc Recent Developments
9.15 Medicago Inc
9.15.1 Medicago Inc Influenzavirus B Infection Drug Basic Information
9.15.2 Medicago Inc Influenzavirus B Infection Drug Product Overview
9.15.3 Medicago Inc Influenzavirus B Infection Drug Product Market Performance
9.15.4 Medicago Inc Business Overview
9.15.5 Medicago Inc Recent Developments
9.16 MedImmune LLC
9.16.1 MedImmune LLC Influenzavirus B Infection Drug Basic Information
9.16.2 MedImmune LLC Influenzavirus B Infection Drug Product Overview
9.16.3 MedImmune LLC Influenzavirus B Infection Drug Product Market Performance
9.16.4 MedImmune LLC Business Overview
9.16.5 MedImmune LLC Recent Developments
9.17 Mucosis BV
9.17.1 Mucosis BV Influenzavirus B Infection Drug Basic Information
9.17.2 Mucosis BV Influenzavirus B Infection Drug Product Overview
9.17.3 Mucosis BV Influenzavirus B Infection Drug Product Market Performance
9.17.4 Mucosis BV Business Overview
9.17.5 Mucosis BV Recent Developments
9.18 Novavax Inc
9.18.1 Novavax Inc Influenzavirus B Infection Drug Basic Information
9.18.2 Novavax Inc Influenzavirus B Infection Drug Product Overview
9.18.3 Novavax Inc Influenzavirus B Infection Drug Product Market Performance
9.18.4 Novavax Inc Business Overview
9.18.5 Novavax Inc Recent Developments
9.19 Park Active Molecules
9.19.1 Park Active Molecules Influenzavirus B Infection Drug Basic Information
9.19.2 Park Active Molecules Influenzavirus B Infection Drug Product Overview
9.19.3 Park Active Molecules Influenzavirus B Infection Drug Product Market Performance
9.19.4 Park Active Molecules Business Overview
9.19.5 Park Active Molecules Recent Developments
9.20 Romark Laboratories LC
9.20.1 Romark Laboratories LC Influenzavirus B Infection Drug Basic Information
9.20.2 Romark Laboratories LC Influenzavirus B Infection Drug Product Overview
9.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Product Market Performance
9.20.4 Romark Laboratories LC Business Overview
9.20.5 Romark Laboratories LC Recent Developments
9.21 Sanofi
9.21.1 Sanofi Influenzavirus B Infection Drug Basic Information
9.21.2 Sanofi Influenzavirus B Infection Drug Product Overview
9.21.3 Sanofi Influenzavirus B Infection Drug Product Market Performance
9.21.4 Sanofi Business Overview
9.21.5 Sanofi Recent Developments
9.22 Sanofi Pasteur SA
9.22.1 Sanofi Pasteur SA Influenzavirus B Infection Drug Basic Information
9.22.2 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Overview
9.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Market Performance
9.22.4 Sanofi Pasteur SA Business Overview
9.22.5 Sanofi Pasteur SA Recent Developments
9.23 Shionogi and Co Ltd
9.23.1 Shionogi and Co Ltd Influenzavirus B Infection Drug Basic Information
9.23.2 Shionogi and Co Ltd Influenzavirus B Infection Drug Product Overview
9.23.3 Shionogi and Co Ltd Influenzavirus B Infection Drug Product Market Performance
9.23.4 Shionogi and Co Ltd Business Overview
9.23.5 Shionogi and Co Ltd Recent Developments
9.24 SK Chemicals Co Ltd
9.24.1 SK Chemicals Co Ltd Influenzavirus B Infection Drug Basic Information
9.24.2 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Overview
9.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Market Performance
9.24.4 SK Chemicals Co Ltd Business Overview
9.24.5 SK Chemicals Co Ltd Recent Developments
9.25 TSRL Inc
9.25.1 TSRL Inc Influenzavirus B Infection Drug Basic Information
9.25.2 TSRL Inc Influenzavirus B Infection Drug Product Overview
9.25.3 TSRL Inc Influenzavirus B Infection Drug Product Market Performance
9.25.4 TSRL Inc Business Overview
9.25.5 TSRL Inc Recent Developments
9.26 Vaxart Inc
9.26.1 Vaxart Inc Influenzavirus B Infection Drug Basic Information
9.26.2 Vaxart Inc Influenzavirus B Infection Drug Product Overview
9.26.3 Vaxart Inc Influenzavirus B Infection Drug Product Market Performance
9.26.4 Vaxart Inc Business Overview
9.26.5 Vaxart Inc Recent Developments
9.27 Vectura Group Plc
9.27.1 Vectura Group Plc Influenzavirus B Infection Drug Basic Information
9.27.2 Vectura Group Plc Influenzavirus B Infection Drug Product Overview
9.27.3 Vectura Group Plc Influenzavirus B Infection Drug Product Market Performance
9.27.4 Vectura Group Plc Business Overview
9.27.5 Vectura Group Plc Recent Developments
10 INFLUENZAVIRUS B INFECTION DRUG MARKET FORECAST BY REGION
10.1 Global Influenzavirus B Infection Drug Market Size Forecast
10.2 Global Influenzavirus B Infection Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Influenzavirus B Infection Drug Market Size Forecast by Country
10.2.3 Asia Pacific Influenzavirus B Infection Drug Market Size Forecast by Region
10.2.4 South America Influenzavirus B Infection Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Influenzavirus B Infection Drug by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Influenzavirus B Infection Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Influenzavirus B Infection Drug by Type (2025-2030)
11.1.2 Global Influenzavirus B Infection Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Influenzavirus B Infection Drug by Type (2025-2030)
11.2 Global Influenzavirus B Infection Drug Market Forecast by Application (2025-2030)
11.2.1 Global Influenzavirus B Infection Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Influenzavirus B Infection Drug Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Influenzavirus B Infection Drug
1.2 Key Market Segments
1.2.1 Influenzavirus B Infection Drug Segment by Type
1.2.2 Influenzavirus B Infection Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INFLUENZAVIRUS B INFECTION DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Influenzavirus B Infection Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Influenzavirus B Infection Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INFLUENZAVIRUS B INFECTION DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Global Influenzavirus B Infection Drug Sales by Manufacturers (2019-2024)
3.2 Global Influenzavirus B Infection Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Influenzavirus B Infection Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Influenzavirus B Infection Drug Sales Sites, Area Served, Product Type
3.6 Influenzavirus B Infection Drug Market Competitive Situation and Trends
3.6.1 Influenzavirus B Infection Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Influenzavirus B Infection Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 INFLUENZAVIRUS B INFECTION DRUG INDUSTRY CHAIN ANALYSIS
4.1 Influenzavirus B Infection Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INFLUENZAVIRUS B INFECTION DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 INFLUENZAVIRUS B INFECTION DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Influenzavirus B Infection Drug Sales Market Share by Type (2019-2024)
6.3 Global Influenzavirus B Infection Drug Market Size Market Share by Type (2019-2024)
6.4 Global Influenzavirus B Infection Drug Price by Type (2019-2024)
7 INFLUENZAVIRUS B INFECTION DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Influenzavirus B Infection Drug Market Sales by Application (2019-2024)
7.3 Global Influenzavirus B Infection Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Influenzavirus B Infection Drug Sales Growth Rate by Application (2019-2024)
8 INFLUENZAVIRUS B INFECTION DRUG MARKET SEGMENTATION BY REGION
8.1 Global Influenzavirus B Infection Drug Sales by Region
8.1.1 Global Influenzavirus B Infection Drug Sales by Region
8.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Influenzavirus B Infection Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Influenzavirus B Infection Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Influenzavirus B Infection Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Influenzavirus B Infection Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 AbbVie Inc
9.1.1 AbbVie Inc Influenzavirus B Infection Drug Basic Information
9.1.2 AbbVie Inc Influenzavirus B Infection Drug Product Overview
9.1.3 AbbVie Inc Influenzavirus B Infection Drug Product Market Performance
9.1.4 AbbVie Inc Business Overview
9.1.5 AbbVie Inc Influenzavirus B Infection Drug SWOT Analysis
9.1.6 AbbVie Inc Recent Developments
9.2 Adimmune Corp
9.2.1 Adimmune Corp Influenzavirus B Infection Drug Basic Information
9.2.2 Adimmune Corp Influenzavirus B Infection Drug Product Overview
9.2.3 Adimmune Corp Influenzavirus B Infection Drug Product Market Performance
9.2.4 Adimmune Corp Business Overview
9.2.5 Adimmune Corp Influenzavirus B Infection Drug SWOT Analysis
9.2.6 Adimmune Corp Recent Developments
9.3 Altravax Inc
9.3.1 Altravax Inc Influenzavirus B Infection Drug Basic Information
9.3.2 Altravax Inc Influenzavirus B Infection Drug Product Overview
9.3.3 Altravax Inc Influenzavirus B Infection Drug Product Market Performance
9.3.4 Altravax Inc Influenzavirus B Infection Drug SWOT Analysis
9.3.5 Altravax Inc Business Overview
9.3.6 Altravax Inc Recent Developments
9.4 Amarillo Biosciences Inc
9.4.1 Amarillo Biosciences Inc Influenzavirus B Infection Drug Basic Information
9.4.2 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Overview
9.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Market Performance
9.4.4 Amarillo Biosciences Inc Business Overview
9.4.5 Amarillo Biosciences Inc Recent Developments
9.5 Aphios Corp
9.5.1 Aphios Corp Influenzavirus B Infection Drug Basic Information
9.5.2 Aphios Corp Influenzavirus B Infection Drug Product Overview
9.5.3 Aphios Corp Influenzavirus B Infection Drug Product Market Performance
9.5.4 Aphios Corp Business Overview
9.5.5 Aphios Corp Recent Developments
9.6 BioCryst Pharmaceuticals Inc
9.6.1 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
9.6.2 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
9.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Market Performance
9.6.4 BioCryst Pharmaceuticals Inc Business Overview
9.6.5 BioCryst Pharmaceuticals Inc Recent Developments
9.7 Cadila Healthcare Ltd
9.7.1 Cadila Healthcare Ltd Influenzavirus B Infection Drug Basic Information
9.7.2 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Overview
9.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Market Performance
9.7.4 Cadila Healthcare Ltd Business Overview
9.7.5 Cadila Healthcare Ltd Recent Developments
9.8 ContraFect Corp
9.8.1 ContraFect Corp Influenzavirus B Infection Drug Basic Information
9.8.2 ContraFect Corp Influenzavirus B Infection Drug Product Overview
9.8.3 ContraFect Corp Influenzavirus B Infection Drug Product Market Performance
9.8.4 ContraFect Corp Business Overview
9.8.5 ContraFect Corp Recent Developments
9.9 Daiichi Sankyo Company Ltd
9.9.1 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Basic Information
9.9.2 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Overview
9.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Market Performance
9.9.4 Daiichi Sankyo Company Ltd Business Overview
9.9.5 Daiichi Sankyo Company Ltd Recent Developments
9.10 Fujifilm Holdings Corporation
9.10.1 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Basic Information
9.10.2 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Overview
9.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Market Performance
9.10.4 Fujifilm Holdings Corporation Business Overview
9.10.5 Fujifilm Holdings Corporation Recent Developments
9.11 GlaxoSmithKline Plc
9.11.1 GlaxoSmithKline Plc Influenzavirus B Infection Drug Basic Information
9.11.2 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Overview
9.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Market Performance
9.11.4 GlaxoSmithKline Plc Business Overview
9.11.5 GlaxoSmithKline Plc Recent Developments
9.12 Green Cross Corp
9.12.1 Green Cross Corp Influenzavirus B Infection Drug Basic Information
9.12.2 Green Cross Corp Influenzavirus B Infection Drug Product Overview
9.12.3 Green Cross Corp Influenzavirus B Infection Drug Product Market Performance
9.12.4 Green Cross Corp Business Overview
9.12.5 Green Cross Corp Recent Developments
9.13 Inovio Pharmaceuticals Inc
9.13.1 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
9.13.2 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
9.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Market Performance
9.13.4 Inovio Pharmaceuticals Inc Business Overview
9.13.5 Inovio Pharmaceuticals Inc Recent Developments
9.14 Kineta Inc
9.14.1 Kineta Inc Influenzavirus B Infection Drug Basic Information
9.14.2 Kineta Inc Influenzavirus B Infection Drug Product Overview
9.14.3 Kineta Inc Influenzavirus B Infection Drug Product Market Performance
9.14.4 Kineta Inc Business Overview
9.14.5 Kineta Inc Recent Developments
9.15 Medicago Inc
9.15.1 Medicago Inc Influenzavirus B Infection Drug Basic Information
9.15.2 Medicago Inc Influenzavirus B Infection Drug Product Overview
9.15.3 Medicago Inc Influenzavirus B Infection Drug Product Market Performance
9.15.4 Medicago Inc Business Overview
9.15.5 Medicago Inc Recent Developments
9.16 MedImmune LLC
9.16.1 MedImmune LLC Influenzavirus B Infection Drug Basic Information
9.16.2 MedImmune LLC Influenzavirus B Infection Drug Product Overview
9.16.3 MedImmune LLC Influenzavirus B Infection Drug Product Market Performance
9.16.4 MedImmune LLC Business Overview
9.16.5 MedImmune LLC Recent Developments
9.17 Mucosis BV
9.17.1 Mucosis BV Influenzavirus B Infection Drug Basic Information
9.17.2 Mucosis BV Influenzavirus B Infection Drug Product Overview
9.17.3 Mucosis BV Influenzavirus B Infection Drug Product Market Performance
9.17.4 Mucosis BV Business Overview
9.17.5 Mucosis BV Recent Developments
9.18 Novavax Inc
9.18.1 Novavax Inc Influenzavirus B Infection Drug Basic Information
9.18.2 Novavax Inc Influenzavirus B Infection Drug Product Overview
9.18.3 Novavax Inc Influenzavirus B Infection Drug Product Market Performance
9.18.4 Novavax Inc Business Overview
9.18.5 Novavax Inc Recent Developments
9.19 Park Active Molecules
9.19.1 Park Active Molecules Influenzavirus B Infection Drug Basic Information
9.19.2 Park Active Molecules Influenzavirus B Infection Drug Product Overview
9.19.3 Park Active Molecules Influenzavirus B Infection Drug Product Market Performance
9.19.4 Park Active Molecules Business Overview
9.19.5 Park Active Molecules Recent Developments
9.20 Romark Laboratories LC
9.20.1 Romark Laboratories LC Influenzavirus B Infection Drug Basic Information
9.20.2 Romark Laboratories LC Influenzavirus B Infection Drug Product Overview
9.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Product Market Performance
9.20.4 Romark Laboratories LC Business Overview
9.20.5 Romark Laboratories LC Recent Developments
9.21 Sanofi
9.21.1 Sanofi Influenzavirus B Infection Drug Basic Information
9.21.2 Sanofi Influenzavirus B Infection Drug Product Overview
9.21.3 Sanofi Influenzavirus B Infection Drug Product Market Performance
9.21.4 Sanofi Business Overview
9.21.5 Sanofi Recent Developments
9.22 Sanofi Pasteur SA
9.22.1 Sanofi Pasteur SA Influenzavirus B Infection Drug Basic Information
9.22.2 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Overview
9.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Market Performance
9.22.4 Sanofi Pasteur SA Business Overview
9.22.5 Sanofi Pasteur SA Recent Developments
9.23 Shionogi and Co Ltd
9.23.1 Shionogi and Co Ltd Influenzavirus B Infection Drug Basic Information
9.23.2 Shionogi and Co Ltd Influenzavirus B Infection Drug Product Overview
9.23.3 Shionogi and Co Ltd Influenzavirus B Infection Drug Product Market Performance
9.23.4 Shionogi and Co Ltd Business Overview
9.23.5 Shionogi and Co Ltd Recent Developments
9.24 SK Chemicals Co Ltd
9.24.1 SK Chemicals Co Ltd Influenzavirus B Infection Drug Basic Information
9.24.2 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Overview
9.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Market Performance
9.24.4 SK Chemicals Co Ltd Business Overview
9.24.5 SK Chemicals Co Ltd Recent Developments
9.25 TSRL Inc
9.25.1 TSRL Inc Influenzavirus B Infection Drug Basic Information
9.25.2 TSRL Inc Influenzavirus B Infection Drug Product Overview
9.25.3 TSRL Inc Influenzavirus B Infection Drug Product Market Performance
9.25.4 TSRL Inc Business Overview
9.25.5 TSRL Inc Recent Developments
9.26 Vaxart Inc
9.26.1 Vaxart Inc Influenzavirus B Infection Drug Basic Information
9.26.2 Vaxart Inc Influenzavirus B Infection Drug Product Overview
9.26.3 Vaxart Inc Influenzavirus B Infection Drug Product Market Performance
9.26.4 Vaxart Inc Business Overview
9.26.5 Vaxart Inc Recent Developments
9.27 Vectura Group Plc
9.27.1 Vectura Group Plc Influenzavirus B Infection Drug Basic Information
9.27.2 Vectura Group Plc Influenzavirus B Infection Drug Product Overview
9.27.3 Vectura Group Plc Influenzavirus B Infection Drug Product Market Performance
9.27.4 Vectura Group Plc Business Overview
9.27.5 Vectura Group Plc Recent Developments
10 INFLUENZAVIRUS B INFECTION DRUG MARKET FORECAST BY REGION
10.1 Global Influenzavirus B Infection Drug Market Size Forecast
10.2 Global Influenzavirus B Infection Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Influenzavirus B Infection Drug Market Size Forecast by Country
10.2.3 Asia Pacific Influenzavirus B Infection Drug Market Size Forecast by Region
10.2.4 South America Influenzavirus B Infection Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Influenzavirus B Infection Drug by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Influenzavirus B Infection Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Influenzavirus B Infection Drug by Type (2025-2030)
11.1.2 Global Influenzavirus B Infection Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Influenzavirus B Infection Drug by Type (2025-2030)
11.2 Global Influenzavirus B Infection Drug Market Forecast by Application (2025-2030)
11.2.1 Global Influenzavirus B Infection Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Influenzavirus B Infection Drug Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Influenzavirus B Infection Drug Market Size Comparison by Region (M USD)
Table 5. Global Influenzavirus B Infection Drug Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Influenzavirus B Infection Drug Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenzavirus B Infection Drug as of 2022)
Table 10. Global Market Influenzavirus B Infection Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Influenzavirus B Infection Drug Sales Sites and Area Served
Table 12. Manufacturers Influenzavirus B Infection Drug Product Type
Table 13. Global Influenzavirus B Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Influenzavirus B Infection Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Influenzavirus B Infection Drug Market Challenges
Table 22. Global Influenzavirus B Infection Drug Sales by Type (Kilotons)
Table 23. Global Influenzavirus B Infection Drug Market Size by Type (M USD)
Table 24. Global Influenzavirus B Infection Drug Sales (Kilotons) by Type (2019-2024)
Table 25. Global Influenzavirus B Infection Drug Sales Market Share by Type (2019-2024)
Table 26. Global Influenzavirus B Infection Drug Market Size (M USD) by Type (2019-2024)
Table 27. Global Influenzavirus B Infection Drug Market Size Share by Type (2019-2024)
Table 28. Global Influenzavirus B Infection Drug Price (USD/Ton) by Type (2019-2024)
Table 29. Global Influenzavirus B Infection Drug Sales (Kilotons) by Application
Table 30. Global Influenzavirus B Infection Drug Market Size by Application
Table 31. Global Influenzavirus B Infection Drug Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Influenzavirus B Infection Drug Sales Market Share by Application (2019-2024)
Table 33. Global Influenzavirus B Infection Drug Sales by Application (2019-2024) & (M USD)
Table 34. Global Influenzavirus B Infection Drug Market Share by Application (2019-2024)
Table 35. Global Influenzavirus B Infection Drug Sales Growth Rate by Application (2019-2024)
Table 36. Global Influenzavirus B Infection Drug Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Influenzavirus B Infection Drug Sales Market Share by Region (2019-2024)
Table 38. North America Influenzavirus B Infection Drug Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Influenzavirus B Infection Drug Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Influenzavirus B Infection Drug Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Influenzavirus B Infection Drug Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Influenzavirus B Infection Drug Sales by Region (2019-2024) & (Kilotons)
Table 43. AbbVie Inc Influenzavirus B Infection Drug Basic Information
Table 44. AbbVie Inc Influenzavirus B Infection Drug Product Overview
Table 45. AbbVie Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. AbbVie Inc Business Overview
Table 47. AbbVie Inc Influenzavirus B Infection Drug SWOT Analysis
Table 48. AbbVie Inc Recent Developments
Table 49. Adimmune Corp Influenzavirus B Infection Drug Basic Information
Table 50. Adimmune Corp Influenzavirus B Infection Drug Product Overview
Table 51. Adimmune Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Adimmune Corp Business Overview
Table 53. Adimmune Corp Influenzavirus B Infection Drug SWOT Analysis
Table 54. Adimmune Corp Recent Developments
Table 55. Altravax Inc Influenzavirus B Infection Drug Basic Information
Table 56. Altravax Inc Influenzavirus B Infection Drug Product Overview
Table 57. Altravax Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Altravax Inc Influenzavirus B Infection Drug SWOT Analysis
Table 59. Altravax Inc Business Overview
Table 60. Altravax Inc Recent Developments
Table 61. Amarillo Biosciences Inc Influenzavirus B Infection Drug Basic Information
Table 62. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Overview
Table 63. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Amarillo Biosciences Inc Business Overview
Table 65. Amarillo Biosciences Inc Recent Developments
Table 66. Aphios Corp Influenzavirus B Infection Drug Basic Information
Table 67. Aphios Corp Influenzavirus B Infection Drug Product Overview
Table 68. Aphios Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Aphios Corp Business Overview
Table 70. Aphios Corp Recent Developments
Table 71. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
Table 72. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
Table 73. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. BioCryst Pharmaceuticals Inc Business Overview
Table 75. BioCryst Pharmaceuticals Inc Recent Developments
Table 76. Cadila Healthcare Ltd Influenzavirus B Infection Drug Basic Information
Table 77. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Overview
Table 78. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Cadila Healthcare Ltd Business Overview
Table 80. Cadila Healthcare Ltd Recent Developments
Table 81. ContraFect Corp Influenzavirus B Infection Drug Basic Information
Table 82. ContraFect Corp Influenzavirus B Infection Drug Product Overview
Table 83. ContraFect Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. ContraFect Corp Business Overview
Table 85. ContraFect Corp Recent Developments
Table 86. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Basic Information
Table 87. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Overview
Table 88. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Daiichi Sankyo Company Ltd Business Overview
Table 90. Daiichi Sankyo Company Ltd Recent Developments
Table 91. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Basic Information
Table 92. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Overview
Table 93. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Fujifilm Holdings Corporation Business Overview
Table 95. Fujifilm Holdings Corporation Recent Developments
Table 96. GlaxoSmithKline Plc Influenzavirus B Infection Drug Basic Information
Table 97. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Overview
Table 98. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. GlaxoSmithKline Plc Business Overview
Table 100. GlaxoSmithKline Plc Recent Developments
Table 101. Green Cross Corp Influenzavirus B Infection Drug Basic Information
Table 102. Green Cross Corp Influenzavirus B Infection Drug Product Overview
Table 103. Green Cross Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Green Cross Corp Business Overview
Table 105. Green Cross Corp Recent Developments
Table 106. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
Table 107. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
Table 108. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Inovio Pharmaceuticals Inc Business Overview
Table 110. Inovio Pharmaceuticals Inc Recent Developments
Table 111. Kineta Inc Influenzavirus B Infection Drug Basic Information
Table 112. Kineta Inc Influenzavirus B Infection Drug Product Overview
Table 113. Kineta Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Kineta Inc Business Overview
Table 115. Kineta Inc Recent Developments
Table 116. Medicago Inc Influenzavirus B Infection Drug Basic Information
Table 117. Medicago Inc Influenzavirus B Infection Drug Product Overview
Table 118. Medicago Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Medicago Inc Business Overview
Table 120. Medicago Inc Recent Developments
Table 121. MedImmune LLC Influenzavirus B Infection Drug Basic Information
Table 122. MedImmune LLC Influenzavirus B Infection Drug Product Overview
Table 123. MedImmune LLC Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. MedImmune LLC Business Overview
Table 125. MedImmune LLC Recent Developments
Table 126. Mucosis BV Influenzavirus B Infection Drug Basic Information
Table 127. Mucosis BV Influenzavirus B Infection Drug Product Overview
Table 128. Mucosis BV Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Mucosis BV Business Overview
Table 130. Mucosis BV Recent Developments
Table 131. Novavax Inc Influenzavirus B Infection Drug Basic Information
Table 132. Novavax Inc Influenzavirus B Infection Drug Product Overview
Table 133. Novavax Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Novavax Inc Business Overview
Table 135. Novavax Inc Recent Developments
Table 136. Park Active Molecules Influenzavirus B Infection Drug Basic Information
Table 137. Park Active Molecules Influenzavirus B Infection Drug Product Overview
Table 138. Park Active Molecules Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. Park Active Molecules Business Overview
Table 140. Park Active Molecules Recent Developments
Table 141. Romark Laboratories LC Influenzavirus B Infection Drug Basic Information
Table 142. Romark Laboratories LC Influenzavirus B Infection Drug Product Overview
Table 143. Romark Laboratories LC Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 144. Romark Laboratories LC Business Overview
Table 145. Romark Laboratories LC Recent Developments
Table 146. Sanofi Influenzavirus B Infection Drug Basic Information
Table 147. Sanofi Influenzavirus B Infection Drug Product Overview
Table 148. Sanofi Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 149. Sanofi Business Overview
Table 150. Sanofi Recent Developments
Table 151. Sanofi Pasteur SA Influenzavirus B Infection Drug Basic Information
Table 152. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Overview
Table 153. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 154. Sanofi Pasteur SA Business Overview
Table 155. Sanofi Pasteur SA Recent Developments
Table 156. Shionogi and Co Ltd Influenzavirus B Infection Drug Basic Information
Table 157. Shionogi and Co Ltd Influenzavirus B Infection Drug Product Overview
Table 158. Shionogi and Co Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 159. Shionogi and Co Ltd Business Overview
Table 160. Shionogi and Co Ltd Recent Developments
Table 161. SK Chemicals Co Ltd Influenzavirus B Infection Drug Basic Information
Table 162. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Overview
Table 163. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 164. SK Chemicals Co Ltd Business Overview
Table 165. SK Chemicals Co Ltd Recent Developments
Table 166. TSRL Inc Influenzavirus B Infection Drug Basic Information
Table 167. TSRL Inc Influenzavirus B Infection Drug Product Overview
Table 168. TSRL Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 169. TSRL Inc Business Overview
Table 170. TSRL Inc Recent Developments
Table 171. Vaxart Inc Influenzavirus B Infection Drug Basic Information
Table 172. Vaxart Inc Influenzavirus B Infection Drug Product Overview
Table 173. Vaxart Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 174. Vaxart Inc Business Overview
Table 175. Vaxart Inc Recent Developments
Table 176. Vectura Group Plc Influenzavirus B Infection Drug Basic Information
Table 177. Vectura Group Plc Influenzavirus B Infection Drug Product Overview
Table 178. Vectura Group Plc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 179. Vectura Group Plc Business Overview
Table 180. Vectura Group Plc Recent Developments
Table 181. Global Influenzavirus B Infection Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 182. Global Influenzavirus B Infection Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 183. North America Influenzavirus B Infection Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 184. North America Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 185. Europe Influenzavirus B Infection Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 186. Europe Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 187. Asia Pacific Influenzavirus B Infection Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 188. Asia Pacific Influenzavirus B Infection Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 189. South America Influenzavirus B Infection Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 190. South America Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 191. Middle East and Africa Influenzavirus B Infection Drug Consumption Forecast by Country (2025-2030) & (Units)
Table 192. Middle East and Africa Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 193. Global Influenzavirus B Infection Drug Sales Forecast by Type (2025-2030) & (Kilotons)
Table 194. Global Influenzavirus B Infection Drug Market Size Forecast by Type (2025-2030) & (M USD)
Table 195. Global Influenzavirus B Infection Drug Price Forecast by Type (2025-2030) & (USD/Ton)
Table 196. Global Influenzavirus B Infection Drug Sales (Kilotons) Forecast by Application (2025-2030)
Table 197. Global Influenzavirus B Infection Drug Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Influenzavirus B Infection Drug Market Size Comparison by Region (M USD)
Table 5. Global Influenzavirus B Infection Drug Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Influenzavirus B Infection Drug Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenzavirus B Infection Drug as of 2022)
Table 10. Global Market Influenzavirus B Infection Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Influenzavirus B Infection Drug Sales Sites and Area Served
Table 12. Manufacturers Influenzavirus B Infection Drug Product Type
Table 13. Global Influenzavirus B Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Influenzavirus B Infection Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Influenzavirus B Infection Drug Market Challenges
Table 22. Global Influenzavirus B Infection Drug Sales by Type (Kilotons)
Table 23. Global Influenzavirus B Infection Drug Market Size by Type (M USD)
Table 24. Global Influenzavirus B Infection Drug Sales (Kilotons) by Type (2019-2024)
Table 25. Global Influenzavirus B Infection Drug Sales Market Share by Type (2019-2024)
Table 26. Global Influenzavirus B Infection Drug Market Size (M USD) by Type (2019-2024)
Table 27. Global Influenzavirus B Infection Drug Market Size Share by Type (2019-2024)
Table 28. Global Influenzavirus B Infection Drug Price (USD/Ton) by Type (2019-2024)
Table 29. Global Influenzavirus B Infection Drug Sales (Kilotons) by Application
Table 30. Global Influenzavirus B Infection Drug Market Size by Application
Table 31. Global Influenzavirus B Infection Drug Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Influenzavirus B Infection Drug Sales Market Share by Application (2019-2024)
Table 33. Global Influenzavirus B Infection Drug Sales by Application (2019-2024) & (M USD)
Table 34. Global Influenzavirus B Infection Drug Market Share by Application (2019-2024)
Table 35. Global Influenzavirus B Infection Drug Sales Growth Rate by Application (2019-2024)
Table 36. Global Influenzavirus B Infection Drug Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Influenzavirus B Infection Drug Sales Market Share by Region (2019-2024)
Table 38. North America Influenzavirus B Infection Drug Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Influenzavirus B Infection Drug Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Influenzavirus B Infection Drug Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Influenzavirus B Infection Drug Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Influenzavirus B Infection Drug Sales by Region (2019-2024) & (Kilotons)
Table 43. AbbVie Inc Influenzavirus B Infection Drug Basic Information
Table 44. AbbVie Inc Influenzavirus B Infection Drug Product Overview
Table 45. AbbVie Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. AbbVie Inc Business Overview
Table 47. AbbVie Inc Influenzavirus B Infection Drug SWOT Analysis
Table 48. AbbVie Inc Recent Developments
Table 49. Adimmune Corp Influenzavirus B Infection Drug Basic Information
Table 50. Adimmune Corp Influenzavirus B Infection Drug Product Overview
Table 51. Adimmune Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Adimmune Corp Business Overview
Table 53. Adimmune Corp Influenzavirus B Infection Drug SWOT Analysis
Table 54. Adimmune Corp Recent Developments
Table 55. Altravax Inc Influenzavirus B Infection Drug Basic Information
Table 56. Altravax Inc Influenzavirus B Infection Drug Product Overview
Table 57. Altravax Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Altravax Inc Influenzavirus B Infection Drug SWOT Analysis
Table 59. Altravax Inc Business Overview
Table 60. Altravax Inc Recent Developments
Table 61. Amarillo Biosciences Inc Influenzavirus B Infection Drug Basic Information
Table 62. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Overview
Table 63. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Amarillo Biosciences Inc Business Overview
Table 65. Amarillo Biosciences Inc Recent Developments
Table 66. Aphios Corp Influenzavirus B Infection Drug Basic Information
Table 67. Aphios Corp Influenzavirus B Infection Drug Product Overview
Table 68. Aphios Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Aphios Corp Business Overview
Table 70. Aphios Corp Recent Developments
Table 71. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
Table 72. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
Table 73. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. BioCryst Pharmaceuticals Inc Business Overview
Table 75. BioCryst Pharmaceuticals Inc Recent Developments
Table 76. Cadila Healthcare Ltd Influenzavirus B Infection Drug Basic Information
Table 77. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Overview
Table 78. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Cadila Healthcare Ltd Business Overview
Table 80. Cadila Healthcare Ltd Recent Developments
Table 81. ContraFect Corp Influenzavirus B Infection Drug Basic Information
Table 82. ContraFect Corp Influenzavirus B Infection Drug Product Overview
Table 83. ContraFect Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. ContraFect Corp Business Overview
Table 85. ContraFect Corp Recent Developments
Table 86. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Basic Information
Table 87. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Overview
Table 88. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Daiichi Sankyo Company Ltd Business Overview
Table 90. Daiichi Sankyo Company Ltd Recent Developments
Table 91. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Basic Information
Table 92. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Overview
Table 93. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Fujifilm Holdings Corporation Business Overview
Table 95. Fujifilm Holdings Corporation Recent Developments
Table 96. GlaxoSmithKline Plc Influenzavirus B Infection Drug Basic Information
Table 97. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Overview
Table 98. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. GlaxoSmithKline Plc Business Overview
Table 100. GlaxoSmithKline Plc Recent Developments
Table 101. Green Cross Corp Influenzavirus B Infection Drug Basic Information
Table 102. Green Cross Corp Influenzavirus B Infection Drug Product Overview
Table 103. Green Cross Corp Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Green Cross Corp Business Overview
Table 105. Green Cross Corp Recent Developments
Table 106. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Basic Information
Table 107. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Overview
Table 108. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Inovio Pharmaceuticals Inc Business Overview
Table 110. Inovio Pharmaceuticals Inc Recent Developments
Table 111. Kineta Inc Influenzavirus B Infection Drug Basic Information
Table 112. Kineta Inc Influenzavirus B Infection Drug Product Overview
Table 113. Kineta Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Kineta Inc Business Overview
Table 115. Kineta Inc Recent Developments
Table 116. Medicago Inc Influenzavirus B Infection Drug Basic Information
Table 117. Medicago Inc Influenzavirus B Infection Drug Product Overview
Table 118. Medicago Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Medicago Inc Business Overview
Table 120. Medicago Inc Recent Developments
Table 121. MedImmune LLC Influenzavirus B Infection Drug Basic Information
Table 122. MedImmune LLC Influenzavirus B Infection Drug Product Overview
Table 123. MedImmune LLC Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. MedImmune LLC Business Overview
Table 125. MedImmune LLC Recent Developments
Table 126. Mucosis BV Influenzavirus B Infection Drug Basic Information
Table 127. Mucosis BV Influenzavirus B Infection Drug Product Overview
Table 128. Mucosis BV Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Mucosis BV Business Overview
Table 130. Mucosis BV Recent Developments
Table 131. Novavax Inc Influenzavirus B Infection Drug Basic Information
Table 132. Novavax Inc Influenzavirus B Infection Drug Product Overview
Table 133. Novavax Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Novavax Inc Business Overview
Table 135. Novavax Inc Recent Developments
Table 136. Park Active Molecules Influenzavirus B Infection Drug Basic Information
Table 137. Park Active Molecules Influenzavirus B Infection Drug Product Overview
Table 138. Park Active Molecules Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. Park Active Molecules Business Overview
Table 140. Park Active Molecules Recent Developments
Table 141. Romark Laboratories LC Influenzavirus B Infection Drug Basic Information
Table 142. Romark Laboratories LC Influenzavirus B Infection Drug Product Overview
Table 143. Romark Laboratories LC Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 144. Romark Laboratories LC Business Overview
Table 145. Romark Laboratories LC Recent Developments
Table 146. Sanofi Influenzavirus B Infection Drug Basic Information
Table 147. Sanofi Influenzavirus B Infection Drug Product Overview
Table 148. Sanofi Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 149. Sanofi Business Overview
Table 150. Sanofi Recent Developments
Table 151. Sanofi Pasteur SA Influenzavirus B Infection Drug Basic Information
Table 152. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Overview
Table 153. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 154. Sanofi Pasteur SA Business Overview
Table 155. Sanofi Pasteur SA Recent Developments
Table 156. Shionogi and Co Ltd Influenzavirus B Infection Drug Basic Information
Table 157. Shionogi and Co Ltd Influenzavirus B Infection Drug Product Overview
Table 158. Shionogi and Co Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 159. Shionogi and Co Ltd Business Overview
Table 160. Shionogi and Co Ltd Recent Developments
Table 161. SK Chemicals Co Ltd Influenzavirus B Infection Drug Basic Information
Table 162. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Overview
Table 163. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 164. SK Chemicals Co Ltd Business Overview
Table 165. SK Chemicals Co Ltd Recent Developments
Table 166. TSRL Inc Influenzavirus B Infection Drug Basic Information
Table 167. TSRL Inc Influenzavirus B Infection Drug Product Overview
Table 168. TSRL Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 169. TSRL Inc Business Overview
Table 170. TSRL Inc Recent Developments
Table 171. Vaxart Inc Influenzavirus B Infection Drug Basic Information
Table 172. Vaxart Inc Influenzavirus B Infection Drug Product Overview
Table 173. Vaxart Inc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 174. Vaxart Inc Business Overview
Table 175. Vaxart Inc Recent Developments
Table 176. Vectura Group Plc Influenzavirus B Infection Drug Basic Information
Table 177. Vectura Group Plc Influenzavirus B Infection Drug Product Overview
Table 178. Vectura Group Plc Influenzavirus B Infection Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 179. Vectura Group Plc Business Overview
Table 180. Vectura Group Plc Recent Developments
Table 181. Global Influenzavirus B Infection Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 182. Global Influenzavirus B Infection Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 183. North America Influenzavirus B Infection Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 184. North America Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 185. Europe Influenzavirus B Infection Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 186. Europe Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 187. Asia Pacific Influenzavirus B Infection Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 188. Asia Pacific Influenzavirus B Infection Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 189. South America Influenzavirus B Infection Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 190. South America Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 191. Middle East and Africa Influenzavirus B Infection Drug Consumption Forecast by Country (2025-2030) & (Units)
Table 192. Middle East and Africa Influenzavirus B Infection Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 193. Global Influenzavirus B Infection Drug Sales Forecast by Type (2025-2030) & (Kilotons)
Table 194. Global Influenzavirus B Infection Drug Market Size Forecast by Type (2025-2030) & (M USD)
Table 195. Global Influenzavirus B Infection Drug Price Forecast by Type (2025-2030) & (USD/Ton)
Table 196. Global Influenzavirus B Infection Drug Sales (Kilotons) Forecast by Application (2025-2030)
Table 197. Global Influenzavirus B Infection Drug Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Influenzavirus B Infection Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Influenzavirus B Infection Drug Market Size (M USD), 2019-2030
Figure 5. Global Influenzavirus B Infection Drug Market Size (M USD) (2019-2030)
Figure 6. Global Influenzavirus B Infection Drug Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Influenzavirus B Infection Drug Market Size by Country (M USD)
Figure 11. Influenzavirus B Infection Drug Sales Share by Manufacturers in 2023
Figure 12. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers in 2023
Figure 13. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Influenzavirus B Infection Drug Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Influenzavirus B Infection Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Influenzavirus B Infection Drug Market Share by Type
Figure 18. Sales Market Share of Influenzavirus B Infection Drug by Type (2019-2024)
Figure 19. Sales Market Share of Influenzavirus B Infection Drug by Type in 2023
Figure 20. Market Size Share of Influenzavirus B Infection Drug by Type (2019-2024)
Figure 21. Market Size Market Share of Influenzavirus B Infection Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Influenzavirus B Infection Drug Market Share by Application
Figure 24. Global Influenzavirus B Infection Drug Sales Market Share by Application (2019-2024)
Figure 25. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2023
Figure 26. Global Influenzavirus B Infection Drug Market Share by Application (2019-2024)
Figure 27. Global Influenzavirus B Infection Drug Market Share by Application in 2023
Figure 28. Global Influenzavirus B Infection Drug Sales Growth Rate by Application (2019-2024)
Figure 29. Global Influenzavirus B Infection Drug Sales Market Share by Region (2019-2024)
Figure 30. North America Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Influenzavirus B Infection Drug Sales Market Share by Country in 2023
Figure 32. U.S. Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Influenzavirus B Infection Drug Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Influenzavirus B Infection Drug Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Influenzavirus B Infection Drug Sales Market Share by Country in 2023
Figure 37. Germany Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Influenzavirus B Infection Drug Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region in 2023
Figure 44. China Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Influenzavirus B Infection Drug Sales and Growth Rate (Kilotons)
Figure 50. South America Influenzavirus B Infection Drug Sales Market Share by Country in 2023
Figure 51. Brazil Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Influenzavirus B Infection Drug Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Influenzavirus B Infection Drug Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Influenzavirus B Infection Drug Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Influenzavirus B Infection Drug Market Share Forecast by Type (2025-2030)
Figure 65. Global Influenzavirus B Infection Drug Sales Forecast by Application (2025-2030)
Figure 66. Global Influenzavirus B Infection Drug Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Influenzavirus B Infection Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Influenzavirus B Infection Drug Market Size (M USD), 2019-2030
Figure 5. Global Influenzavirus B Infection Drug Market Size (M USD) (2019-2030)
Figure 6. Global Influenzavirus B Infection Drug Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Influenzavirus B Infection Drug Market Size by Country (M USD)
Figure 11. Influenzavirus B Infection Drug Sales Share by Manufacturers in 2023
Figure 12. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers in 2023
Figure 13. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Influenzavirus B Infection Drug Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Influenzavirus B Infection Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Influenzavirus B Infection Drug Market Share by Type
Figure 18. Sales Market Share of Influenzavirus B Infection Drug by Type (2019-2024)
Figure 19. Sales Market Share of Influenzavirus B Infection Drug by Type in 2023
Figure 20. Market Size Share of Influenzavirus B Infection Drug by Type (2019-2024)
Figure 21. Market Size Market Share of Influenzavirus B Infection Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Influenzavirus B Infection Drug Market Share by Application
Figure 24. Global Influenzavirus B Infection Drug Sales Market Share by Application (2019-2024)
Figure 25. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2023
Figure 26. Global Influenzavirus B Infection Drug Market Share by Application (2019-2024)
Figure 27. Global Influenzavirus B Infection Drug Market Share by Application in 2023
Figure 28. Global Influenzavirus B Infection Drug Sales Growth Rate by Application (2019-2024)
Figure 29. Global Influenzavirus B Infection Drug Sales Market Share by Region (2019-2024)
Figure 30. North America Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Influenzavirus B Infection Drug Sales Market Share by Country in 2023
Figure 32. U.S. Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Influenzavirus B Infection Drug Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Influenzavirus B Infection Drug Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Influenzavirus B Infection Drug Sales Market Share by Country in 2023
Figure 37. Germany Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Influenzavirus B Infection Drug Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region in 2023
Figure 44. China Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Influenzavirus B Infection Drug Sales and Growth Rate (Kilotons)
Figure 50. South America Influenzavirus B Infection Drug Sales Market Share by Country in 2023
Figure 51. Brazil Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Influenzavirus B Infection Drug Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Influenzavirus B Infection Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Influenzavirus B Infection Drug Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Influenzavirus B Infection Drug Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Influenzavirus B Infection Drug Market Share Forecast by Type (2025-2030)
Figure 65. Global Influenzavirus B Infection Drug Sales Forecast by Application (2025-2030)
Figure 66. Global Influenzavirus B Infection Drug Market Share Forecast by Application (2025-2030)
